1192873-43-0 Usage
General Description
3-(pyridin-4-yl)-1-trityl-1H-indazol-5-amine is a chemical compound with a molecular formula C32H26N4. It is a derivative of indazole, which is a heterocyclic compound containing a pyrazole ring fused to a pyridine ring. The presence of a trityl group and a pyridine moiety in the structure of 3-(pyridin-4-yl)-1-trityl-1H-indazol-5-amine suggests its potential applications in organic synthesis, medicinal chemistry, and pharmaceutical products. The compound may have diverse biological activities and could serve as a valuable intermediate in the synthesis of various pharmacologically active compounds. Furthermore, its unique structure and chemical properties make it a promising candidate for further research and development in the field of organic and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1192873-43-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,2,8,7 and 3 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1192873-43:
(9*1)+(8*1)+(7*9)+(6*2)+(5*8)+(4*7)+(3*3)+(2*4)+(1*3)=180
180 % 10 = 0
So 1192873-43-0 is a valid CAS Registry Number.
1192873-43-0Relevant articles and documents
Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy
Fitch, William L.,Gajera, Chandresh R.,Lam, Grace,Le?niak, Robert K.,Montine, Thomas J.,Nguyen, Khanh C.,Nichols, R. Jeremy,Schonemann, Marcus,Smith, Mark,Zhao, Jing
supporting information, (2022/01/08)
Mutations in the Leucine Rich Repeat Protein Kinase 2 gene (LRRK2) are the most common genetic causes of Parkinson's Disease (PD). The G2019S mutation is the most common inherited LRRK2 mutation, occurs in the kinase domain, and results in increased kinase activity. We report the discovery and development of compound 38, an indazole-based, G2019S-selective (>2000-fold vs. WT) LRRK2 inhibitor capable of entering rodent brain (Kp = 0.5) and selectively inhibiting G2019S-LRRK2. The compounds disclosed herein present a starting point for further development of brain penetrant G2019S selective inhibitors that hopefully reduce lung phenotype side-effects and pave the way to providing a precision medicine for people with PD who carry the G2019S mutation.
